<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E6FAA770-7076-48C5-9E61-2308F4048053"><gtr:id>E6FAA770-7076-48C5-9E61-2308F4048053</gtr:id><gtr:name>European Screening Centre (ESC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E6FAA770-7076-48C5-9E61-2308F4048053"><gtr:id>E6FAA770-7076-48C5-9E61-2308F4048053</gtr:id><gtr:name>European Screening Centre (ESC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B708948A-FF9C-42C8-A788-1A4ECC46E3B2"><gtr:id>B708948A-FF9C-42C8-A788-1A4ECC46E3B2</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:otherNames>Martin</gtr:otherNames><gtr:surname>Palmer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5A1E6D8C-5EBC-43B9-9D6B-8EE996C05589"><gtr:id>5A1E6D8C-5EBC-43B9-9D6B-8EE996C05589</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Yarwood</gtr:surname><gtr:orcidId>0000-0001-9489-9253</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FD015324%2F1"><gtr:id>68C04B6C-7535-4597-9714-BDFEA13079D8</gtr:id><gtr:title>The Cyclic AMP-GEF/C/EBP Pathway; a New PKA-independent Route for the Control of Gene Expression by Cyclic AMP</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D015324/1</gtr:grantReference><gtr:abstractText>The cyclic AMP cascade was the first intracellular mechanism described to explain how hormones exert functional changes inside cells and remains the archetypical signalling system. Until very recently in was thought that increases in the intracellular concentration of cyclic AMP exerted changes in the activity of genes solely through prior phosphorylation of the transription factor 'CREB' by the enzyme 'PKA'. However, a new route has now been discovered whereby cyclic AMP can activate proteins called Ras and Rap. These are involved in the control of cell survival, the cell cycle control and cell adhesion. However, in order to activate Ras and Rap, cyclic AMP must first directly interact with another class of enzymes called cyclic AMP GEFs. Two such cyclic AMP GEFs are EPAC or CNrasGEF. The aims of this project are to determine the mechanisms by which activation of cyclic AMP-GEFs can lead to changes in gene expression, in a cyclic AMP-dependent, independently of PKA. To do this we will use the SOCS-3 gene as a paradigm. SOCS-3 is a gene whose induction leads to the suppression of signaling from cytokine and growth factor receptors. We have recently found that the SOCS-3 gene is also positively regulated by cyclic AMP, through EPAC and Rap1. Our work shows that this is probably through transcription factors called C/EBP. Moreover, we have found that a PKA-independent pathway leads to the activation of the growth regulatory enzyme ERK from cyclic AMP. ERK is required for SOCS-3 induction by cyclic AMP and phosphorylates one class of C/EBPs, also in a cyclic AMP-dependent, PKA-independent fashion. We will therefore delineate this new pathway leading from activation of cyclic AMP-GEFs, like EPAC or CNrasGEF, through ERK to C/EBPs and determine the biological consequences of its activation in human umbilical cord endothelial cells (HUVECs). This cell system has been shown to express cyclic AMP-inducible SOCS-3 and presents the advantage that the biological significance of gene induction, as determined by SOCS-3 mediated inhibition of cytokine signalling, can be easily measured. Because the cyclic AMP-GEF-C/EBP pathway is the first example of a cyclic AMP-activated signalling pathway that can control gene expression independently of the classical PKA/CREB route, these studies are an urgent scientific priority. Our investigations will therefore provide a critical new understanding of how gene expression is regulated by the prototypical cyclic AMP signalling system. Our joint expertise in studying the molecular and cellular basis of cyclic AMP signalling means that we are well equipped to carry out these investigations.</gtr:abstractText><gtr:technicalSummary>The aims of this project are to determine the mechanisms by which activation of cyclic AMP-GEFs, such as EPAC or CNrasGEF, lead to changes in gene expression in a protein kinase A (PKA)-independent manner using the SOCS-3 gene as a paradigm. We have obtained substantial preliminary data demonstrating that C/EBP transcription factors are activated by EPAC. Moreover, the induction of SOCS-3 is dependent on the prior activation of ERK, which promotes the phosphorylation of the C/EBP isoform, C/EBP beta, in a cyclic AMP-dependent, PKA-independent manner. This represents a fundamental new control mechanism by which cyclic AMP regulates gene transcription. Our objectives in this project therefore are to delineate this new cyclic AMP-GEF/C/EBP pathway and determine the biological consequences of its activation in a human umbilical cord endothelial cell (HUVEC) model system. These cells express EPAC-inducible SOCS-3 and have the benefit that the biological significance of gene induction, as determined by SOCS-3 mediated inhibition of IL-6 signaling through the JAK-STAT pathway, can be easily assessed. These studies are an urgent scientific priority because the cyclic AMP-GEF-C/EBP-SOCS-3 pathway represents the first example of a cyclic AMP-activated signalling pathway that can control gene expression independently of the classical route of cyclic AMP-mediated transcriptional control, via PKA and cyclic AMP-response-element-binding-proteins (CREB). Our investigations will therefore provide a critical new understanding of how gene expression is regulated by the prototypical cyclic AMP signalling system.</gtr:technicalSummary><gtr:fund><gtr:end>2009-08-26</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-06-27</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>416288</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Screening Centre (ESC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>European Lead Factory</gtr:description><gtr:id>66399F6F-E5A5-47B2-A2E9-EC3D7CF28CA7</gtr:id><gtr:impact>Grant applications in preperation</gtr:impact><gtr:outcomeId>56b87a785271a1.52652088-1</gtr:outcomeId><gtr:partnerContribution>ultra high throughput screening; protein purification; x-ray crystallography; medicinal chemistry</gtr:partnerContribution><gtr:piContribution>We devised a high throughput screening assay which was used to identify small molecule regulators of the enzyme, EPAC1</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cardiovascular and Medical Sciences (ICAMS)</gtr:department><gtr:description>BHF-funded Collaboration with Dr Tim Palmer</gtr:description><gtr:id>5EB6F909-D356-4493-B524-E83AE2E9EF89</gtr:id><gtr:impact>Milne GR, Palmer TM, Yarwood SJ. Novel control of cAMP-regulated transcription in vascular endothelial cells. Biochem Soc Trans. 2012 Feb;40(1):1-5.

Parnell E, Smith BO, Palmer TM, Terrin A, Zaccolo M, Yarwood SJ. Regulation of the inflammatory response of vascular endothelial cells by EPAC1. Br J Pharmacol. 2012 May;166(2):434-46.

Sands WA, Woolson HD, Yarwood SJ, Palmer TM. Exchange protein directly activated by cyclic AMP-1-regulated recruitment of CCAAT/enhancer-binding proteins to the suppressor of cytokine signaling-3 promoter. Methods Mol Biol. 2012;809:201-14.

Woolson HD, Thomson VS, Rutherford C, Yarwood SJ, Palmer TM. Selective inhibition of cytokine-activated extracellular signal-regulated kinase by cyclic AMP via Epac1-dependent induction of suppressor of cytokine signalling-3. Cell Signal. 2009 Nov;21(11):1706-15.

Borland G, Bird RJ, Palmer TM, Yarwood SJ. Activation of protein kinase Calpha by EPAC1 is required for the ERK- and CCAAT/enhancer-binding protein beta-dependent induction of the SOCS-3 gene by cyclic AMP in COS1 cells. J Biol Chem. 2009 Jun 26;284(26):17391-403.

Yarwood SJ, Borland G, Sands WA, Palmer TM. Identification of CCAAT/enhancer-binding proteins as exchange protein activated by cAMP-activated transcription factors that mediate the induction of the SOCS-3 gene. J Biol Chem. 2008 Mar 14;283(11):6843-53.</gtr:impact><gtr:outcomeId>j5bnD1JBUUi-1</gtr:outcomeId><gtr:partnerContribution>Research resources</gtr:partnerContribution><gtr:piContribution>We have a close collaboration with the Palmer laboratory and regularly share ideas and resources.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SULSA-funded Collaboration with Dr Stuart McElroy</gtr:description><gtr:id>7CBF3034-EE91-47FE-8E45-71B769741469</gtr:id><gtr:impact>We have now carried out uHTS with the European Lead Factory. Compounds are currently under development.</gtr:impact><gtr:outcomeId>56af7149569003.30227770-1</gtr:outcomeId><gtr:partnerContribution>Dr McElroy helped us develop our HTS assay to make an application to the European Lead Factory for uHTS.</gtr:partnerContribution><gtr:piContribution>We established a high-throughput screening assay</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The role of insulin-dependent signalling pathways in the control of mesenchymal stem cell differentiation towards bone and fat</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Tenovus Scotland</gtr:fundingOrg><gtr:id>C0144C3F-BB7A-4258-9501-A76BF3EE0686</gtr:id><gtr:outcomeId>58a43fac0b37b8.17808968</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Mechanisms of regulation of the anti inflammatory gene SOCS3 by cyclic AMP</gtr:description><gtr:end>2007-10-02</gtr:end><gtr:fundingOrg>Tenovus Scotland</gtr:fundingOrg><gtr:id>A06DD649-72A7-43EF-AAB6-11E26953A47B</gtr:id><gtr:outcomeId>iEnaYhFyohv</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>416289</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>oThe EPAC-C/EBP pathway - a new route for the control of gene expression by cyclic AMP</gtr:description><gtr:end>2009-10-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/D015324</gtr:fundingRef><gtr:id>64795440-CDA5-4DFE-975D-16039E5882C3</gtr:id><gtr:outcomeId>A67y6UbDsvi</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2005-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>107122</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Novel EPAC1 inhibitors to enhance insulin sensitivity in vascular endothelial cells</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>FS/17/12/32703</gtr:fundingRef><gtr:id>C0DC9A64-09BD-4006-A4DD-AECAEE3A7F89</gtr:id><gtr:outcomeId>58a4485992d019.61922790</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>109784</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Scotland PhD Studentship</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>Medical Research Scotland</gtr:fundingOrg><gtr:fundingRef>PhD-868-2015</gtr:fundingRef><gtr:id>4E641D76-63EB-433A-BA3E-55B2D2C3E3EF</gtr:id><gtr:outcomeId>56b887739a1114.72119635</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>162924</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SOCS3 induction - a new physiological role for the cAMP sensor Epac in limiting endothelial dysfunction</gtr:description><gtr:end>2008-01-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/05/026</gtr:fundingRef><gtr:id>FC593FB9-8F8A-4741-9EC5-597662755991</gtr:id><gtr:outcomeId>QPfGHSmasFx</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2005-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Identification of Small Molecule Agonists - European Lead Factory, contract worth &amp;pound;300,000, Program Owner</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>ELFSC08_02</gtr:fundingRef><gtr:id>617833FE-E480-45D4-947E-2E263BD8F973</gtr:id><gtr:outcomeId>58a435ad9a2368.43254987</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>178111</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Role of EPAC1-regulated Protein Kinase C Isoforms in Mediating C/EBPdelta -dependent, Anti-inflammatory Actions of Cyclic AMP in Vascular Endothelial Cells</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>pg/10/026/28303</gtr:fundingRef><gtr:id>3B673C60-42B7-4526-9525-20A023C1B037</gtr:id><gtr:outcomeId>L4SutyUUrff</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220852</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Regulation of anti-inflammatory gene expression in vascular endothelial cells by EPAC1</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/15/15/31316</gtr:fundingRef><gtr:id>A081811A-7300-4EBE-B14F-CA1F58C4F575</gtr:id><gtr:outcomeId>56af71e308a611.84795200</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Identification of small molecule activators of EPAC1 to serve as novel anti-inflamatory agents in vascular endothelial cells</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>40D877C7-DEB8-41E1-9AE9-9A102A81C496</gtr:id><gtr:outcomeId>jDJyrwdnN99</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>We have established EPAC1 as a valid drug-target in vascular endothelial cells. We are no developing a drug discovery program to realise this.</gtr:description><gtr:id>AA0A15BA-8217-4092-A856-2AF5580C2E52</gtr:id><gtr:impactTypes/><gtr:outcomeId>5465efd62dd384.20165764</gtr:outcomeId></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>1) Activation of EPAC1 in vascular endothelial cells (VECs) leads to the induction of the SOCS-3 gene, which mediates anti-inflammatory actions of cyclic AMP in these cells. These findings now place EPAC1 at the centre of a regulatory network designed to limit inflammatory responses in
VECs.

2) SOCS-3 induction by EPAC1 requires C/EBP transcription factors, ? and d, which are activated by cyclic AMP, independently of the classical route through protein kinase A and CREB. This is a completely novel signalling pathway that has broad ramifications for a wide range of signalling
scenarios.

3) C/EBP activation and SOCS-3 induction by EPAC1 involves a new pathway including phospholipase Ce and protein kinase C isoforms a and d. We believe this new cyclic AMP regulated
signalling pathway can be exploited by novel therapeutics designed to treat cardiovascular disease. We have therefore begun collaboration with clinical researchers to test the
validity of this hypothesis.</gtr:description><gtr:exploitationPathways>Our findings will support future research into EPAC1-directed drug research.</gtr:exploitationPathways><gtr:id>1ACF9ACC-5762-47D4-B649-5B939B303A2F</gtr:id><gtr:outcomeId>5465f03450ac73.66558452</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Marie Curie - Advisory Board for Institutional Fellowship</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>A74BE47D-B153-49F3-9E41-F4AAF291EBE0</gtr:id><gtr:outcomeId>T7NqYAexw1w</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Biochemical Society - Council of the Biochemical Society. Member of Council</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1281F544-F28E-420F-86E9-525FA46AF553</gtr:id><gtr:outcomeId>rFo3fJPykNk</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Biochemical Society - Chair of the Signal Transduction Theme Panel</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DC21B5FE-447E-4E67-8BB7-A98E963367E4</gtr:id><gtr:outcomeId>J8FY1SJjWCg</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6584764F-F2CE-42E0-8B00-8D1B464439A1</gtr:id><gtr:title>The future of EPAC-targeted therapies: agonism versus antagonism.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/088abfdc74276a19abef11f37e045fe6"><gtr:id>088abfdc74276a19abef11f37e045fe6</gtr:id><gtr:otherNames>Parnell E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>56af46267c8311.58131805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE4E49D9-F9C9-4191-B7FD-B43F39B30444</gtr:id><gtr:title>Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d96315773e0efe28fd2ed8efeae36c6"><gtr:id>5d96315773e0efe28fd2ed8efeae36c6</gtr:id><gtr:otherNames>Wiejak J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56af46249a8975.69490744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B76641B-54E4-4AB8-98C7-D40A71514F8C</gtr:id><gtr:title>Nanotopography controls cell cycle changes involved with skeletal stem cell self-renewal and multipotency.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e89a3b960dfe0dd56530310b4ce40a9"><gtr:id>4e89a3b960dfe0dd56530310b4ce40a9</gtr:id><gtr:otherNames>Lee LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>5a7b05feb1e950.22363996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32349A11-6833-4CB3-859D-6B98E03E5B7F</gtr:id><gtr:title>Genomic analysis of the role of transcription factor C/EBPd in the regulation of cell behaviour on nanometric grooves.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d96315773e0efe28fd2ed8efeae36c6"><gtr:id>5d96315773e0efe28fd2ed8efeae36c6</gtr:id><gtr:otherNames>Wiejak J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>56af462ac0ea92.95026858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35A29937-A943-4D05-9306-07143D192F80</gtr:id><gtr:title>Regulation of anti-inflammatory gene expression in vascular endothelial cells by EPAC1</gtr:title><gtr:parentPublicationTitle>Journal of Cell Signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/333dfc2f36b5498e6b6d717c39b4338b"><gtr:id>333dfc2f36b5498e6b6d717c39b4338b</gtr:id><gtr:otherNames>Palmer {</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5717815dc6b402.15621120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AB6F3A0-6648-40A9-895F-3A6C0B9B414B</gtr:id><gtr:title>The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of cardiovascular development and disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/357e85784bcf24e7c034c096554175ac"><gtr:id>357e85784bcf24e7c034c096554175ac</gtr:id><gtr:otherNames>Barker G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2308-3425</gtr:issn><gtr:outcomeId>5a7b05fe3823f9.94361809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55A323D7-031E-4285-89A8-95FE18D58643</gtr:id><gtr:title>Targeting SOCS proteins to combat inflammation</gtr:title><gtr:parentPublicationTitle>Endocrine Abstracts</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ed04fb24d04ed171ade20efc2eb7ad5"><gtr:id>0ed04fb24d04ed171ade20efc2eb7ad5</gtr:id><gtr:otherNames>Yarwood S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5717815e269911.10258039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>938E3D1B-D963-435E-8476-3FDB9B4D75A0</gtr:id><gtr:title>Exchange protein directly activated by cyclic AMP-1-regulated recruitment of CCAAT/enhancer-binding proteins to the suppressor of cytokine signaling-3 promoter.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bf5de8499923010ef51a2953cbc360e"><gtr:id>8bf5de8499923010ef51a2953cbc360e</gtr:id><gtr:otherNames>Sands WA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-1-61779-375-2</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5717815e562811.90976068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D81CF18A-F18B-4C47-8D85-E64731EF6749</gtr:id><gtr:title>Activation of protein kinase Calpha by EPAC1 is required for the ERK- and CCAAT/enhancer-binding protein beta-dependent induction of the SOCS-3 gene by cyclic AMP in COS1 cells.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97d18d750ff77dd59b81e807c233c1fd"><gtr:id>97d18d750ff77dd59b81e807c233c1fd</gtr:id><gtr:otherNames>Borland G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56af46253009d3.35041198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DD84578-ABD6-4908-B016-7A85F84E8948</gtr:id><gtr:title>Novel control of cAMP-regulated transcription in vascular endothelial cells.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ef987ee9b88d9bca14abbd7b53a69a8"><gtr:id>8ef987ee9b88d9bca14abbd7b53a69a8</gtr:id><gtr:otherNames>Milne GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>56af4629927f30.39214820</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EA0EE70-D457-45A8-9D14-815E6358269D</gtr:id><gtr:title>RACK 1 associated with focal adhesions alters the cells sensitivity to contact guidance</gtr:title><gtr:parentPublicationTitle>European Cells and Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0547a4787247147010ee9f386c6f34f0"><gtr:id>0547a4787247147010ee9f386c6f34f0</gtr:id><gtr:otherNames>Hart A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:outcomeId>5717815ecaf068.59290235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF9739E9-505D-49AF-B166-53B86671E150</gtr:id><gtr:title>Identification of CCAAT/enhancer-binding proteins as exchange protein activated by cAMP-activated transcription factors that mediate the induction of the SOCS-3 gene.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e50318d35a58cd37def452daf861a99f"><gtr:id>e50318d35a58cd37def452daf861a99f</gtr:id><gtr:otherNames>Yarwood SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56af46238493f7.34394131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EB42FE8-F82C-4E4D-BDF3-732E73A29129</gtr:id><gtr:title>Extracellular signal-regulated kinase mitogen-activated protein kinase-dependent SOCS-3 gene induction requires c-Jun, signal transducer and activator of transcription 3, and specificity protein 3 transcription factors.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d96315773e0efe28fd2ed8efeae36c6"><gtr:id>5d96315773e0efe28fd2ed8efeae36c6</gtr:id><gtr:otherNames>Wiejak J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>56af462aeece51.54975245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3390B710-9FCD-439C-AC54-02639E478292</gtr:id><gtr:title>Adhesion Protein Protocols</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f22dffb45093df201c85b88bc75bba9"><gtr:id>2f22dffb45093df201c85b88bc75bba9</gtr:id><gtr:otherNames>Dalby M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:isbn>1-59745-353-6</gtr:isbn><gtr:outcomeId>571781632f7e29.76469438</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83894A2B-9FB5-4E09-8F81-BAD40A063824</gtr:id><gtr:title>Regulation of anti-inflammatory gene expression in vascular endothelial cells by EPAC1</gtr:title><gtr:parentPublicationTitle>Journal of Cell Signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4f30663c3f2bf977ea3b8396fe09b62"><gtr:id>e4f30663c3f2bf977ea3b8396fe09b62</gtr:id><gtr:otherNames>Timothy M. Palmer</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5a7b05fedde994.30582264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B94467E3-1AE0-4DA0-B397-83FFAB3FEFD6</gtr:id><gtr:title>EPAC proteins transduce diverse cellular actions of cAMP.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97d18d750ff77dd59b81e807c233c1fd"><gtr:id>97d18d750ff77dd59b81e807c233c1fd</gtr:id><gtr:otherNames>Borland G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>56af46274b9953.09979349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EB9F0B9-CCDF-494F-8479-A07FF0CE9561</gtr:id><gtr:title>Regulation of the inflammatory response of vascular endothelial cells by EPAC1.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/088abfdc74276a19abef11f37e045fe6"><gtr:id>088abfdc74276a19abef11f37e045fe6</gtr:id><gtr:otherNames>Parnell E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>56af46230230f9.47199352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8621285-25FB-4200-8C1B-7DFAE0ED918E</gtr:id><gtr:title>RACK 1 associated with focal adhesions alters the cells sensitivity to contact guidance</gtr:title><gtr:parentPublicationTitle>Journal of European Cells and Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0547a4787247147010ee9f386c6f34f0"><gtr:id>0547a4787247147010ee9f386c6f34f0</gtr:id><gtr:otherNames>Hart A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:outcomeId>57c9435e93dc57.01969510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71F8B583-7D50-4735-947E-3BBC822B4F4E</gtr:id><gtr:title>Analysis of focal adhesions and cytoskeleton by custom microarray.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf6521cd685bb971a016a91242f31478"><gtr:id>cf6521cd685bb971a016a91242f31478</gtr:id><gtr:otherNames>Dalby MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>57c9435e4a69b8.85153420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9252F826-E8AD-4574-BA5F-0C94A7E0827C</gtr:id><gtr:title>Cyclic AMP-mediated induction of suppressor of cytokine signalling-3 (SOCS3) through EPAC1 and C/EBP transcription factors</gtr:title><gtr:parentPublicationTitle>Proceedings of the Physiological Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97d18d750ff77dd59b81e807c233c1fd"><gtr:id>97d18d750ff77dd59b81e807c233c1fd</gtr:id><gtr:otherNames>Borland G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>5717815e7bf070.74537272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63C43460-AAF0-4FB7-BA83-DCA03800EB1B</gtr:id><gtr:title>Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase C.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cba492e916d2269cbd1f4251832ee67e"><gtr:id>cba492e916d2269cbd1f4251832ee67e</gtr:id><gtr:otherNames>Bird RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56af46282d9f45.61490964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B0E97A3-403E-472F-A7D2-BFB7F573F834</gtr:id><gtr:title>RACK 1 associated with focal adhesions alters the cells sensitivity to contact guidance</gtr:title><gtr:parentPublicationTitle>European Cells and Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0547a4787247147010ee9f386c6f34f0"><gtr:id>0547a4787247147010ee9f386c6f34f0</gtr:id><gtr:otherNames>Hart A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:outcomeId>57c9435eafd026.62668188</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BA02457-0482-47B3-9DA3-94E2EAABBA17</gtr:id><gtr:title>Cyclic AMP-mediated induction of suppressor of cytokine signalling-3 (SOCS3) through EPAC1 and C/EBP transcription factors</gtr:title><gtr:parentPublicationTitle>Proceedings of the Physiological Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97d18d750ff77dd59b81e807c233c1fd"><gtr:id>97d18d750ff77dd59b81e807c233c1fd</gtr:id><gtr:otherNames>Borland G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>57c9435e695898.93563603</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>713AEA67-557E-4FA7-A6F9-EE08A353E9D0</gtr:id><gtr:title>Probe-Dependent Negative Allosteric Modulators of the Long-Chain Free Fatty Acid Receptor FFA4.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54abc69ae38c715d91d4c67e27e10add"><gtr:id>54abc69ae38c715d91d4c67e27e10add</gtr:id><gtr:otherNames>Watterson KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>5a7b05fe82cb39.23368523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F7E7437-A012-4CEB-AD7C-8D919003AB30</gtr:id><gtr:title>The effect of the RACK1 signalling protein on the regulation of cell adhesion and cell contact guidance on nanometric grooves.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf6521cd685bb971a016a91242f31478"><gtr:id>cf6521cd685bb971a016a91242f31478</gtr:id><gtr:otherNames>Dalby MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>56af462445f913.47835445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B93FC87A-0C2D-4076-9885-49C22821BDCC</gtr:id><gtr:title>Mimitin - a novel cytokine-regulated mitochondrial protein.</gtr:title><gtr:parentPublicationTitle>BMC cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54b970e0b4037fd7d15d1fb39289fd11"><gtr:id>54b970e0b4037fd7d15d1fb39289fd11</gtr:id><gtr:otherNames>Wegrzyn P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-2121</gtr:issn><gtr:outcomeId>56af4628b03dc9.66849455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53D8114A-0E09-446D-8553-3F8E6598F81B</gtr:id><gtr:title>Selective inhibition of cytokine-activated extracellular signal-regulated kinase by cyclic AMP via Epac1-dependent induction of suppressor of cytokine signalling-3.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/273fa06bb845f29ede85b21b9b130e9a"><gtr:id>273fa06bb845f29ede85b21b9b130e9a</gtr:id><gtr:otherNames>Woolson HD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>56af462651c993.24227844</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/D015324/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>